Have a feature idea you'd love to see implemented?
Let us know!
IMUX Immunic Inc
Price (delayed)
$1.11
Market cap
$99.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$41.1M
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's
Highlights
The company's debt has shrunk by 76% YoY and by 23% QoQ
The EPS has increased by 42% YoY but it has decreased by 28% from the previous quarter
Immunic's net income has decreased by 36% QoQ and by 22% YoY
IMUX's equity is down by 35% since the previous quarter and by 15% year-on-year
Key stats
What are the main financial stats of IMUX
Market
Valuations
Earnings
Shares outstanding
90.08M
Market cap
$99.99M
Enterprise value
$41.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$96.9M
EBITDA
-$96.78M
Free cash flow
-$76.26M
Per share
Balance sheet
Liquidity
EPS
-$1.23
Free cash flow per share
-$0.75
Book value per share
$0.46
Revenue per share
$0
TBVPS
$0.64
Total assets
$64.76M
Total liabilities
$23.54M
Debt
$186,000
Equity
$41.22M
Working capital
$39.91M
Debt to equity
0
Current ratio
2.71
Quick ratio
2.53
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-125.2%
Return on equity
-178.4%
Return on invested capital
N/A
Return on capital employed
-234%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMUX stock price
How has the Immunic stock price performed over time
Intraday
3.74%
1 week
1.83%
1 month
-28.39%
1 year
3.74%
YTD
-26%
QTD
-32.73%
Financial performance
How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$95.8M
Net income
-$96.9M
Gross margin
N/A
Net margin
N/A
IMUX's operating income is down by 40% since the previous quarter and by 18% year-on-year
Immunic's net income has decreased by 36% QoQ and by 22% YoY
Growth
What is Immunic's growth rate over time
Valuation
What is Immunic stock price valuation
P/E
N/A
P/B
2.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 42% YoY but it has decreased by 28% from the previous quarter
The price to book (P/B) is 43% higher than the 5-year quarterly average of 1.7 and 10% higher than the last 4 quarters average of 2.2
IMUX's equity is down by 35% since the previous quarter and by 15% year-on-year
Efficiency
How efficient is Immunic business performance
The company's return on equity has shrunk by 81% YoY and by 40% QoQ
The company's return on assets has shrunk by 55% YoY and by 37% QoQ
Dividends
What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMUX.
Financial health
How did Immunic financials performed over time
The total assets is 175% greater than the total liabilities
The quick ratio has contracted by 28% from the previous quarter and by 25% YoY
IMUX's current ratio is down by 28% since the previous quarter and by 26% year-on-year
The company's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% YoY
The company's debt has shrunk by 76% YoY and by 23% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.